Patent Assignment
Reel/Frame 067402/0782
Release of Security Interest
Recorded: 2024-05-14
Pages: 23
Assignor
OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
Executed: 2024-05-01
Assignee
REGULUS THERAPEUTICS INC.
4224 CAMPUS POINT COURT, SUITE 210, SAN DIEGO, CALIFORNIA, 92121
Covered Properties
(57)
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Methods for Use in Modulating Mir-122A
Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Method for Inhibiting the Activity of Mir-155
Microrna Detection
7-Hydroxy Chromones as Potent Antioxidants
Oligomeric Compounds and Compositions for Use in Modulation of Pri-Mirnas
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Method of Inhibiting Mir-33 Using a Modified Oligonucleotide
Targeting Micrornas for the Treatment of Fibrosis
Microrna Compounds and Methods for Modulating Mir-21 Activity
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Methods for Treatment of Alport Syndrome
Microrna Compounds and Methods for Modulating Mir-21 Activity
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Compounds and Methods for Enhanced Cellular Uptake
Microrna Compounds and Methods for Modulating Mir-122
Targeting Micrornas for the Treatment of Fibrosis
Microrna Compounds and Methods for Modulating Mir-21 Activity
Microrna Compounds and Methods for Modulating Mir-122
Methods for Use in Modulating Mir-122A
Microrna Compounds and Methods for Modulating Mir-21 Activity
Methods for Treatment of Alport Syndrome
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Targeting Micrornas for Metabolic Disorders
Targeting Micrornas for the Treatment of Fibrosis
Microrna Compounds and Methods for Modulating Mir-21 Activity
Microrna Compounds and Methods for Modulating Mir-21 Activity
Microrna Compounds and Methods for Modulating Mir-21 Activity
Microrna Compounds and Methods for Modulating Mir-122
Methods for Treatment of Alport Syndrome
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Targeting Micrornas for Metabolic Disorders
Compounds and Methods for Enhanced Cellular Uptake
Targeting Micrornas for the Treatment of Fibrosis
Microrna Compounds and Methods for Modulating Mir-122
Microrna Compounds and Methods for Modulating Mir-21 Activity
Oligomeric Compounds and Compositions for Use in Modulation of Small Non-Coding Rnas
Methods for Treatment of Alport Syndrome
OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAs
Microrna Compounds and Methods for Modulating Mir-21 Activity
Application:
15/704,749 →
Publication:
US 2018/0155719
Targeting Micrornas for Metabolic Disorders
Methods for Direct Measurement of Microrna Inhibition and Mimicry
Application:
15/754,061 →
Publication:
US 2018/0363056
Methods for Treatment of Alport Syndrome
Application:
15/948,450 →
Publication:
US 2018/0298385
Targeting MicroRNAs for the Treatment of Fibrosis
Application:
15/954,059 →
Publication:
US 2018/0305690
MicroRNA Compounds and Methods for Modulating MIR-21 Activity
Application:
15/954,159 →
Publication:
US 2018/0305691
MicroRNA Compounds and Methods for Modulating MIR-21 Activity
Application:
15/976,060 →
Publication:
US 2018/0355355
MicroRNA Compounds and Methods for Modulating MIR-122
Application:
62/668,467 →
Methods for Oral Delivery of Oligonucleotides
Application:
62/701,317 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Oct 22, 2004
From: ESAU, CHRISTINE; LOLLO, BRIDGET; BENNETT, C. FRANK; FREIER, SUSAN M.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 015301/0373 →
Assignment of Assignor's Interest
Nov 1, 2006
From: ESAU, CHRISTINE; BHANOT, SANJAY
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 018464/0742 →
Assignment of Assignor's Interest
Nov 8, 2007
From: ISIS PHARMACEUTICALS, INC.
To: REGULUS THERAPEUTICS, LLC
Reel/Frame 020085/0730 →
Change of Name
Feb 12, 2009
From: REGULUS THERAPEUTICS, LLC
To: REGULUS THERAPEUTICS, INC.
Reel/Frame 022260/0041 →
Assignment of Assignor's Interest
May 4, 2009
From: ESAU, CHRISTINE; DAVIS, SCOTT E.; BENNETT, C. FRANK
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 022632/0224 →
Assignment of Assignor's Interest
Mar 15, 2010
From: JIA, QI; FARROW, THOMAS M.
To: UNIGEN PHARMACEUTICALS, INC.
Reel/Frame 024083/0441 →
Assignment of Assignor's Interest
Apr 9, 2010
From: ISIS PHARMACEUTICALS, INC.
To: REGULUS THERAPEUTICS INC.
Reel/Frame 024214/0149 →
Change of Name
May 10, 2010
From: REGULUS THERAPEUTICS, LLC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 024362/0224 →
Assignment of Assignor's Interest
May 10, 2010
From: ISIS PHARMACEUTICALS, INC.
To: REGULUS THERAPEUTICS, LLC
Reel/Frame 024361/0870 →
Assignment of Assignor's Interest
May 10, 2010
From: ESAU, CHRISTINE; LOLLO, BRIDGET; BENNETT, C. FRANK; FREIER, SUSAN M.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 024361/0782 →
Assignment of Assignor's Interest
Apr 11, 2011
From: ISIS PHARMACEUTICALS, INC.
To: REGULUS THERAPEUTICS, LLC
Reel/Frame 026107/0491 →
Assignment of Assignor's Interest
Apr 11, 2011
From: ESAU, CHRISTINE; LOLLO, BRIDGET; BENNETT, C. FRANK; FREIER, SUSAN M.
To: ISIS PHARMACEUTICALS, INC.
Reel/Frame 026107/0384 →
Change of Name
Apr 11, 2011
From: REGULUS THERAPEUTICS, LLC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 026108/0016 →
Change of Name
Jun 3, 2011
From: UNIGEN PHARMACEUTICALS, INC.
To: UNIGEN, INC.
Reel/Frame 026385/0449 →
Assignment of Assignor's Interest
Jun 28, 2012
From: ESAU, CHRISTINE; LOLLO, BRIDGET; BENNETT, C. FRANK; FREIER, SUSAN M.
To: ISIS PHARMACEUTICALS INC.
Reel/Frame 028459/0194 →
Change of Name
Jun 28, 2012
From: REGULUS THERAPEUTICS, LLC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 028459/0541 →
Assignment of Assignor's Interest
Jun 28, 2012
From: ISIS PHARMACEUTICALS INC.
To: REGULUS THERAPEUTICS, LLC
Reel/Frame 028459/0229 →
Assignment of Assignor's Interest
May 16, 2013
From: BHAT, BALKRISHEN; MARCUSSON, ERIC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 030430/0138 →
Assignment of Assignor's Interest
May 28, 2013
From: ESAU, CHRISTINE; LOLLO, BRIDGET; BENNETT, C. FRANK; FREIER, SUSAN M.
To: ISIS PHARMACEUTICALS INC.
Reel/Frame 030495/0443 →
Change of Name
May 28, 2013
From: REGULUS THERAPEUTICS, LLC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 030498/0602 →
Assignment of Assignor's Interest
May 28, 2013
From: ISIS PHARMACEUTICALS INC.
To: REGULUS THERAPEUTICS, LLC
Reel/Frame 030495/0583 →
Assignment of Assignor's Interest
Jan 2, 2014
From: CHAU, B. NELSON
To: REGULUS THERAPEUTICS INC.
Reel/Frame 031880/0095 →
Assignment of Assignor's Interest
Jan 2, 2014
From: DUFFIELD, JEREMY; BHAT, BALKRISHEN; MACKENNA, DEIDRE
To: REGULUS THERAPEUTICS INC.
Reel/Frame 031872/0727 →
Security Interest
Aug 8, 2018
From: REGULUS THERAPEUTICS INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
Reel/Frame 046748/0561 →
Release of Security Interest
Nov 7, 2018
From: OXFORD FINANCE LLC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 047445/0286 →